<DOC>
	<DOCNO>NCT00606021</DOCNO>
	<brief_summary>This multicenter , open-label , randomize , two-arm Phase 2 study compare pemetrexed plus best supportive care best supportive care alone maintenance therapy follow first-line treatment pemetrexed-cisplatin combination patient advance non-squamous non-small cell lung cancer . A total approximately 100 patient plan enrol , follow completion four cycle pemetrexed-cisplatin ( Induction Phase ) patient disease progression occur randomized 2:1 ratio one two treatment arm ( Maintenance Phase ) : Arm A ( pemetrexed plus best supportive care ) Arm B ( best supportive care alone ) .</brief_summary>
	<brief_title>A Study Comparing Two Different Chemotherapy Regimens , Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Inclusion criterion : 1 . You must least 18 year old 2 . You must diagnose nonsquamous nonsmall cell lung cancer ( NSCLC ) 3 . You must prior systemic anticancer therapy lung cancer 4 . You must live close enough study doctor able visit regularly follow 5 . You must sign informed consent form indicate willingness take part study 6 . Your laboratory medical history test must meet study requirement Exclusion criterion : 1 . Treatment within last 30 day drug receive regulatory approval indication time study entry 2 . Prior radiotherapy surgery complete least 4 week prior initiation treatment 3 . Serious concomitant systemic disorder ( e.g. , active infection include human immunodeficiency virus , unstable cardiovascular disease ) 4 . Prior malignancy NSCLC , carcinoma situ cervix , nonmelanoma skin cancer unless treat least 5 year previously subsequent evidence recurrence 5 . Brain metastasis 6 . Presence clinically significant ( physical exam ) thirdspace fluid collection , example , ascites pleural effusion control drainage procedure prior study entry 7 . Significant weight loss ( great 10 % ) , previous 6 week study entry 8 . Concurrent administration antitumor therapy 9 . Inability interrupt aspirin nonsteroidal antiinflammatory agent 5day period ( 8day period longacting agent piroxicam ) 10 . Inability unwillingness take folic acid , dexamethasone ( equivalent ) vitamin B12 supplementation 11 . Pregnancy breastfeed 12 . You allergic pemetrexed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>